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Abstract
Background: Most metastatic spinal cord lesions are located either in the intradural, extrame-
dullary, or in the epidural compartments. Intramedullary spinal cord metastasis (ISCM) is a rare
central nervous system spread of cancer. The aim of this report was to evaluate ISCM in the
published literature.
Methods: A literature review of PubMed from 1960 to 2016 was undertaken for the publications
having demographic, clinical, histological, and outcome data.
Results: A total of 59 relevant papers were identified, showing 128 cases of intramedullary
metastasis from lung cancer. The incidence of lung cancer as the primary malignancy with
intramedullary metastasis was 56%. The median time from diagnosis of primary to intramedul-
lary metastasis was 6 months. Survival improved with multimodality therapy compared to
monotherapy (4 months vs. 6.3 months) (hazard ratio = 0.501; 95% confidence interval,
0.293–0.857).
http://dx.doi.org/10.1016/j.hemonc.2017.07.003
1658-3876/ 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author at: Markey Cancer Center, 800 Rose Street, cc-410, Lexington, KY 40536, USA.
E-mail address: hsa222@uky.edu (H. Saeed).
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Conclusion: Lung cancer is the predominant cause of intramedullary involvement of the spinal
cord. Overall prognosis is poor, although a multimodality approach was associated with
improved survival.
 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
Metastatic spread of cancer to the central nervous system is
common and usually causes death. Spinal metastatic disease
frequently manifests as spinal cord compression, owing to
the extension of growth from the vertebral column with
epidural lesions, or leptomeningeal involvement with
intradural, extramedullary lesions. A small fraction, how-
ever, can metastasize to the intramedullary portion of the
spinal cord (ISCM) and have different clinical presentations
and outcomes.
Little is known of this rare condition, but primary lung
cancer is thought to be the most common malignancy to
cause ISCM. In the limited literature, ISCM is believed to
represent less than 5% of all spinal metastasis [1]. Spread
of disease to ISCM is thought to be from direct tumor infil-
tration or by hematogenous spread of cancer cells. The ISCM
retains the blood–brain barrier, which hinders the initial
spread of metastatic disease, but also inhibits the infusion
of chemotherapy along with regulatory mechanisms.
As patients are living longer and disease recurrence in the
central nervous system is increasing, we sought to review the
literature and analyze the clinical characteristics of ISCM.
Materials and methods
We charged three authors with reviewing Pubmed search
engine using the keywords (intramedullary, metastasis, lung)
independently. Results were then combined, and conflicts in
interpretation were resolved by mutual discussions. The
search covered articles in English literature with human sub-
ject matter from January 1960 through December 2015.
Results were then reviewed to extract raw data including
age, sex, presentation, time from cancer diagnosis, pathology
of the lung cancer, site of spinal cord involvement, diagnostic
method, cerebrospinal fluid cytology, and associated brain
and/or leptomeningeal metastatic disease. The time from
diagnosis of spinal metastases until death, loss of follow-up,
or living at time of reporting were measured and converted
to months using the following formula: 1 week = 0.23 month.
Kaplan–Meier curves and log-rank tests were used to
evaluate the association between categorical variables
and survival time. The univariate Cox model was used to
obtain the estimated hazard ratio (HR) between two groups.
SPSS version 22 (IBM Corp., Armonk, NY, USA) was used to
perform statistical analysis.
Results
Out of the 133 articles returned by searching, 59 were rele-
vant and involved lung cancer. These included 22 case series
(Table 1) and 37 single case reports (Table 2), with the total
number of intramedullary metastatic cases being 128. Lung
cancer was the primary malignancy in 56% of the reported
cases in the mixed series (Table 1).
Age and sex distributions were recorded for all the
patients (n = 128) with the median age being 60 years.
Men were reported with 3:1 distribution. The median time
to diagnosis (n = 91) was 6 months (range, 0–49 months).
Pathology of the lung primary was available for most of
the cohort (n = 123), with small cell lung carcinoma (SCLC)
being the primary pathology in 40.7% (n = 50) versus nons-
mall cell lung carcinoma (NSCLC) with a distribution of
20.3% adenocarcinoma, and 6.3% squamous of the total
reported cases. It does not appear that metastatic disease
from SCLC resulted in significantly worse survival (p = 0.27).
Magnetic resonance imaging was the modality for diagno-
sis in 52% (n = 39), whereas computed tomography was used
in 5.3% and positron emission tomography in 4%. Twenty-
three patients (30.7%) were diagnosed postmortem.
Regions of disease were reported in 85.9% (n = 110). The
cervical region was the most common area of intramedul-
lary metastases with 34.5% of the available data revealing
involvement. Thoracic and lumbar disease consisted of
approximately two-thirds of cases. Multilevel involvement
was reported in 25.5% (n = 28). There was no statistically
significant overall survival difference when comparing one
region of involvement versus multiregional (p = 0.15).
Interestingly, leptomeningeal disease was reported in
31.3% (n = 40) of the examined cases, but when cere-
brospinal fluid was measured, cytology was positive in only
11.4% out of the 44 cases. There were 42 cases with con-
comitant brain metastasis, which was associated with com-
parable survival to the ones with negative brain metastasis
with an HR of 1.01 (95% confidence interval, 0.56–1.84;
p = 0.956).
Treatments used were reported in 79 of the cases. Most
patients received steroids for symptomatic management.
Multimodality treatment of spinal metastases included radi-
ation, intrathecal and systemic chemotherapy, and/or sur-
gery. A higher proportion received radiation (36.7%) and
multimodality treatment (43%), as compared to surgery
alone (17.7%). The multimodality group had significantly
better survival outcome as compared to single form of ther-
apy, with median survival of 6.3 months versus 4 months,
respectively (Fig. 1; p = 0.008, HR = 0.50; 95% confidence
interval, 0.29–0.86).
Discussion
We hereby collectively studied intramedullary spinal cord
metastasis arising from a lung primary. Our review shows
that the use of multimodality therapy with surgery,
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Table 1 Case series of intramedullary spinal metastasis of lung primary.
Study Total Age (y) Sex Time
since
diagnosis
(months)
Histology Treatment Survival (months) Status
Benson [11] 3 59 m 12 NSCLC 0.69 Deceased
58 m 2 NSCLC Radiation 4 Deceased
56 m 0 NSCLC 2 Deceased
Sherbourne et al. [12] 2 69 m 36 NSCLC 0.23 Deceased
60 m NSCLC 3 Deceased
Belmusto et al. [13] 5 40 m 6 SCLC Surgery 2 Deceased
Edelson et al. [14] 9 76 m 0 NA Radiation 0.46 Deceased
40 m 10 SCLC Radiation 2.07 Deceased
49 m 6 SCLC Radiation 0.23 Deceased
43 f 0 NSCLC Radiation 1.38 Deceased
Puljic et al. [15] 4 63 m 0 NA
64 m NSCLC Radiation
Jellinger et al. [16] 7 69 f 0 SCLC 1.38 Deceased
78 m 0 SCLC 2 Deceased
Moffie and Stefanko [17] 3 71 m 0 NSCLC
Hashizume and Hirano [18] 5 50 m SCLC
59 f NSCLC
39 f NSCLC
72 m SCLC
Murphy et al. [19] 4 58 f 10 SCLC Radiation 1 Deceased
54 f 11 SCLC Radiation 9 Deceased
45 m SCLC Radiation 10 Deceased
62 m 0 SCLC Radiation 7 Deceased
Costigan and Winkelman [20] 13 60 m NSCLC 0.34 Deceased
60 m NSCLC 2 Deceased
63 m NSCLC 3 Deceased
46 f SCLC Radiation
69 m SCLC 7 Deceased
63 f NSCLC
42 m SCLC
49 m SCLC
66 m NSCLC
56 m NSCLC
36 m NSCLC
Grem et al. [21] 5 56 m 36 SCLC Multimodality 13 Deceased
54 f 10 SCLC Radiation
45 m 9 SCLC Radiation 4 Deceased
Findlay et al. [22] 2 74 m 0 NSCLC Multimodality 3 Deceased
Tognetti et al. [23] 5 59 m 0 NSCLC Radiation 7 Deceased
41 m 0 SCLC Surgery 2.5 Deceased
61 m 8 NSCLC 1.47 Deceased
Connolly et al. [24] 3 35 f 0 NSCLC Multimodality 6.5 Deceased
62 m 0 NSCLC Multimodality 11 Deceased
Sutter et al. [25] 3 54 m 0 NSCLC Surgery 6 Deceased
45 m 0 SCLC Surgery 8 Deceased
Potti et al. [6] 7 62 m NSCLC Multimodality 4.6 Deceased
62 m NSCLC Multimodality 6.3 Deceased
69 f NSCLC Multimodality 1.3 Deceased
61 m NSCLC Multimodality 23.5 Deceased
64 m NSCLC Multimodality 16.6 Deceased
68 f NSCLC Multimodality 9.3 Deceased
62 m NSCLC Multimodality 10 Deceased
(continued on next page)
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radiotherapy, and chemotherapy might improve the dismal
survival associated with this disease.
Surveillance research from the American Cancer Society
for 2016 demonstrates lung cancer to be the second leading
cause of new cancer cases and is a leading cause of cancer
mortality, being responsible for 27% of all cancer deaths.
Intramedullary spinal cord metastatic disease is a rarely
studied complication of primary lung cancer and represents
less than 5% of total spinal cord metastasis. We do under-
stand that direct tumor infiltration and hematogenous
spread are the two most common methods of metastasis to
the spinal cord, which are the proposed methods in ISCM
also. Our goal was to review cases of ISCM in order to identify
imaging and/or treatment approaches to impact and poten-
tially improve clinical practice. We included reported case
studies of intramedullary metastasis from 1960 to increase
the reliability of information being extracted and capture
modern approaches of management. The analysis showed
comparable results to previous reports of lung cancer as
being the most common source of metastasis [1,2]; however,
this could also be related to selection bias given the exclu-
sion of published paper with no lung cancer involvement.
Prior to the introduction of advanced imaging techniques
and early detection of lung cancer in the 1980s, sensorimo-
Table 1 (continued)
Study Total Age (y) Sex Time
since
diagnosis
(months)
Histology Treatment Survival (months) Status
Watanabe et al. [5] 7 79 m 0 SCLC
70 m 0 SCLC Surgery 5 Deceased
61 m 16 SCLC
53 m 0 NSCLC Radiation 9 Deceased
61 m 8 SCLC
Lee et al. [26] 12 61 m 9.5 SCLC Radiation 2 Deceased
63 m 13.9 SCLC Radiation 1 Deceased
65 f 10.1 SCLC Radiation 8.8 Deceased
32 f 7.9 NSCLC Radiation 0.8 Deceased
77 m 0.2 NSCLC Radiation 1 Deceased
73 m 0 NSCLC 18.4 Deceased
Dam-Hieu et al. [9] 19 43 m 24 NSCLC Surgery 2 Deceased
68 m 12 NSCLC 0.11 Deceased
50 m 11 SCLC Multimodality 6 Deceased
47 f 18 NSCLC Multimodality 8 Deceased
39 f 12 SCLC 4 Deceased
66 m NSCLC 1 Deceased
57 m 3 NSCLC Multimodality 4 Deceased
56 f 12 SCLC Multimodality 5 Deceased
49 m 18 NA Multimodality 2 Deceased
66 m 6 NSCLC 0.46 Deceased
55 m 24 NSCLC Multimodality 11 Deceased
68 f 24 SCLC Multimodality 15 Deceased
65 f 20 SCLC Multimodality 4 Deceased
Hashii et al. [27] 18 49 m NSCLC 1.84 Deceased
55 m NSCLC 5.98 Deceased
57 m NSCLC 2.07 Deceased
64 f NSCLC 3.91 Deceased
65 m NSCLC 0.92 Deceased
76 m NSCLC 4.6 Deceased
67 m SCLC 4.6 Deceased
72 f SCLC 6.44 Deceased
Sung et al. [1] 8 63 m 1 NA Multimodality 4 Deceased
Payer et al. [28] 22 77 m 0 NSCLC Surgery 3 Alive
64 f 6 NSCLC Multimodality 4 Alive
34 f 49 NSCLC Multimodality 6 Alive
27 m 13 NSCLC Multimodality 13 Alive
60 m 0 NSCLC Multimodality 3 Alive
54 m 46 NSCLC Surgery
f = female; m = male; NA = not available; NSCLC = nonsmall cell lung carcinoma; SCLC = small cell lung carcinoma; y = year.
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tor symptoms were the predominant initial presentations of
ISCM. This is evident with the trend of discovering most of
the cases through postmortem examination earlier and with
imaging techniques later. However, some reported cases of
primary lung cancer still present with ISCM as the initial
finding [3–5].
Hematogenous spread, as stated above, is a proposed
mechanism for metastasis, and the rich blood supply to
the cervical spinal cord is expected to be responsible for
increased incidence of regional involvement [6]. However,
neither the cervical region nor the extent of multiregional
metastasis appeared to affect survival in our review.
Many varied imaging techniques have been used to
detect ISCM; however, magnetic resonance imaging proves
to be an effective diagnostic strategy. Some reports have
also found positron emission tomography–computed tomog-
raphy to have a role in detecting ISCM [7,8].
Management of ISCM continues to be variable and exper-
imental owing to the lack of experience and clinical study.
Dam-Hieu et al. [9] proposed surgical intervention to signif-
icantly affect outcome; in our analysis, however, we did not
observe whether surgery, radiation, or chemotherapy alone
would change or improve survival. Using the multimodality
approach with more than one intervention suggests
improved median survival in this population. Although the
multimodality treatment approach did significantly enhance
the outcome, overall median survival continues to be grim
at about 4 months. Hata et al. [10] showed an unexpected
response to an oral tyrosine kinase inhibitor and radiation
of more than 84 months.
Data collected in this review have significant limitations
as they depend on retrospective collection performed by
their respective authors and lack many details that would
have affected the results of this analysis. ISCM has also been
Table 2 Case reports of intramedullary spinal metastasis from the lung.
Study Age (y) Sex Time since
diagnosis (months)
Histology Treatment Survival
(months)
Status
Smith and Turner [29] 66 m 0 SCLC Surgery 1.38 Deceased
Hirose et al. [30] 57 m 0 NSCLC 3 Deceased
Sebastian et al. [31] 51 m 0 SCLC Multimodality 1.38 Deceased
Reddy et al. [32] 64 m 10 SCLC
Weissman and Grossman [33] 48 m 6 SCLC Multimodality 1 Deceased
Lazzarino et al. [34] 63 m 0 SCLC
Koelman et al. [35] 54 f 24 NSCLC Multimodality 13 Deceased
Aoki et al. [36] 75 m NSCLC 1.6 Deceased
Jayasundera et al. [7] 59 m 11 NSCLC Radiation
Keung et al. [37] 39 f 9 NSCLC Radiation 2.3 Deceased
Vindlacheruvu et al. [38] 54 f 0 SCLC Multimodality 6 Deceased
Fujimoto et al. [39] 59 m 6 SCLC Radiation 6 Deceased
Komori and Delbeke [8] 64 m 11 NSCLC
Mortimer et al. [40] 69 m NSCLC Radiation 0.46 Alive
Reddy et al. [41] 80 m 30 NSCLC Multimodality 2 Alive
Aryan et al. [42] 59 m 0 NSCLC 8 Alive
Kalayci et al. [43] 72 m 6 NSCLC Surgery 8 Deceased
Guppy and Wagner [44] 54 m 0 NSCLC Surgery 4 Deceased
Koutsis et al. [45] 60 m 10 SCLC Radiation 1 Deceased
Nikolaou et al. [46] 47 f 3 SCLC Chemotherapy 4 Deceased
Marquart et al. [4] 74 m 0 NSCLC Multimodality 4.14 Deceased
Ashawesh et al. [47] 68 m 4 SCLC Radiation
Li et al. [48] 33 f 48 NSCLC Multimodality 0.46 Alive
Soga et al. [49] 73 m NSCLC 2 Deceased
Liu et al. [50] 44 m 36 NSCLC Surgery 8 Deceased
Sari et al. [3] 50 f 0 SCLC
Hata et al. [10] 35 m 8 NSCLC Multimodality 84 Alive
Zhang et al. [51] 58 m 0 SCLC Radiation 9 Deceased
Mavani et al. [52] 46 m 0 NSCLC Multimodality 2 Alive
Gainor et al. [53] 31 m 30 NSCLC Radiation 5 Alive
Nishioka et al. [54] 76 m 0 SCLC Surgery 1.6 Deceased
Mori et al. [55] 67 m 12 NSCLC Radiation 10 Deceased
Katsenos and Nikolopoulou [56] 74 m 0 SCLC Multimodality 3 Deceased
Miura et al. [57] 59 f 14 SCLC Chemotherapy 21 Alive
Nayman et al. [58] 60 f 0 NSCLC
Jain et al. [59] 66 f 0 SCLC
Kumar et al. [60] 57 m 0 NSCLC Surgery
f = female; m = male; mo; months; NSCLC = nonsmall cell lung carcinoma; SCLC = small cell lung carcinoma; y = years.
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an observed complication in other cancers such as breast
cancer and our inclusion criteria of primary lung cancers,
thus preventing a fully realized understanding of ISCM. A
limited number of retrospective cases also prevent
evidence-based practice and allows only observational rec-
ommendations. Despite these limitations, the review hopes
to offer a comprehensive look at a poorly understood and
rare metastatic process.
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